<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The study was designed to present the incidence of <z:hpo ids='HP_0000001'>all</z:hpo> the <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> in Basse-Normandie over the period 1997-2004 </plain></SENT>
<SENT sid="1" pm="."><plain>We extracted the data from the "Registre régional des hémopathies malignes de Basse-Normandie (RRHMBN)", a French registry which belongs to the Association of the French <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registries (FRANCIM) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the malignant haematological diseases were coded using the third edition of the International Classification for Oncologic Diseases (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-O-3) and the ADICAP classification, a special version adapted in 2001 for haematology </plain></SENT>
<SENT sid="3" pm="."><plain>Five thousand five hundred and ten new cases of malignant <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> were registered over the period 1997-2004 </plain></SENT>
<SENT sid="4" pm="."><plain>Whatever the department constituting the Basse-Normandie (Calvados, Manche and Orne), no significant difference of incidence was detected </plain></SENT>
<SENT sid="5" pm="."><plain>In men, the more frequent malignant disorders were non-Hodgkin's malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHML) followed by <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> and other mature <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM), <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>), Waldenström's <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">macroglobulinemia</z:e> (WM) and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) </plain></SENT>
<SENT sid="6" pm="."><plain>In women, MM is the third more frequent <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> after NHML and lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and other mature <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, WM and ALL </plain></SENT>
<SENT sid="7" pm="."><plain>The other <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> are very rare </plain></SENT>
<SENT sid="8" pm="."><plain>We provide the incidence for the main <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> and for the first time we also present the incidence of the different subtypes of the Hodgkin's and non-Hodgkin's malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, mature lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> and also <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>These results are useful for the organization and follow-up of medical care </plain></SENT>
<SENT sid="10" pm="."><plain>The development of specialized haematology and active protocols can optimize the management of the older patients </plain></SENT>
<SENT sid="11" pm="."><plain>A high quality of the collected data remains necessary for a continuous watching and research on patients with malignant haematological diseases </plain></SENT>
</text></document>